Table 1.

Baseline Patient and Tumor Characteristics of Evaluable MK-2206-Treated Patients and Untreated Controls

Patient Characteristics	MK-2206 (n=12)	Control (n=6)
Age (years), mean (SD)	53.2 (11.2)	58 (11.9)
Menopausal Status, n (%)
Pre-menopausal	6 (50%)	2 (33%)
Post-menopausal	6 (50%)	4 (67%)
Ethnicity, n (%)
Hispanic	7 (59%)	2 (33%)
Non-Hispanic White	4 (33%)	2 (33%)
Non-Hispanic Black	1 (8%)	1 (17%)
Asian	0 (0%)	1 (17%)
Tumor Characteristics
Initial Histology, n (%)
Invasive Carcinoma
Invasive Ductal Carcinoma	10 (83%)	4 (67%)
Invasive Lobular Carcinoma	2 (17%)	2 (33%)
Initial Size (cm) mean (SD)
Invasive Carcinoma	2.5 (1.1)	3.0 (1.4)
Immunophenotype, n (%)
HR+/HER2−1	8 (67%)	6 (100%)
HR+/HER2+	1 (8%)	0 (0%)
Triple Negative	3 (25%)	0 (0%)
Grade, n (%)
I	2 (17%)	1 (17%)
II	6 (50%)	4 (66%)
III	4 (33%)	1 (17%)
Type of surgery, n (%)
Lumpectomy	5 (41%)	2 (33%)
Mastectomy	7 (59%)	4 (67%)

SD=Standard Deviation, HR=Hormone Receptor, HER2=Human Epidermal Growth Factor Receptor 2, TN=Triple Negative